NICE Agrees With FDA in Pulling Avastin's Indication for Metastatic Breast Cancer | GenomeWeb

By Turna Ray

UK's National Institute for Health and Clinical Excellence agrees with US health regulators when it comes to Avastin as a treatment for metastatic breast cancer.

After reviewing the available evidence on Genentech/Roche's Avastin in combination with a taxane therapy to treat metastatic breast cancer in the first-line setting, NICE found this treatment regimen was not cost effective and did not improve patient outcomes compared to available alternatives.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.